In addition to monoclonal antibodies and small-molecules aimed at blocking the interaction of PD-L1 with PD-1 on the surface of cancer cells, the idea of “switching off” PD-L1 expression by preventing PD-L1 upregulation or PD-L1 translation inside the cell is attracting considerable research interest as a novel immunotherapeutic approach [104]. The gene discussed is CD274; the disease is cancer.